CPHRF
Cipher Pharmaceuticals Inc.
OTC Markets OTCQXUSDEQUITY
Healthcare
DELAYED
Strong sell
-59/100
Last price
9.83
▲ 0.18 (1.87%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
9.83
Prev close
9.65
Day high
9.83
Day low
9.83
Volume
2
Market cap
$249.83M
P/E (TTM)
8.86
52W range
8.92 – 15.00
Day trading desk
Gap from prior close
+0.92%
Prior close 9.74
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
9.83 – 9.83
Position in range
—
—
ATR (14D)
0.17
1.71% of price
Prior day high
9.74
PDH
Prior day low
9.71
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 5.53K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+0.82%
-1.1%
1M
-5.12%
-6.6%
3M
-16.91%
-20.3%
6M
-28.04%
-43.0%
YTD
-10.47%
-24.5%
1Y
-11.52%
-27.3%
3Y
+209.12%
+127.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CPHRF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
10.81M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 30, 26 | Cipher Pharmaceuticals, Inc. Issuer |
BUY | 133.25K | $1.36M | Direct |
| Sep 30, 26 | Cipher Pharmaceuticals, Inc. Issuer |
BUY | 133.25K | $1.36M | Direct |
| Sep 18, 26 | Mull (Craig James) 10% Security Holder of Issuer |
SELL | 20.00K | $202.48K | Direct |
| Sep 18, 26 | Mull (Craig James) 10% Security Holder of Issuer |
EXERCISE | 20.00K | $16.88K | Direct |
| Sep 18, 26 | Mull (Craig James) 10% Security Holder of Issuer |
BUY | 20.00K | $202.48K | Direct |
| Sep 2, 26 | Cipher Pharmaceuticals, Inc. Issuer |
BUY | 4.00K | $41.09K | Direct |
| Aug 31, 26 | Cipher Pharmaceuticals, Inc. Issuer |
BUY | 70.81K | $726.85K | Direct |
| Aug 31, 26 | Cipher Pharmaceuticals, Inc. Issuer |
BUY | 66.81K | $685.79K | Direct |
| Jun 24, 26 | Deeth, Douglas Norman Director of Issuer |
EXERCISE | 2.50K | $28.44K | Direct |
| Jun 24, 26 | Deeth, Douglas Norman Director of Issuer |
EXERCISE | 1.15K | $13.17K | Direct |
| Jun 24, 26 | Mull (Craig James) 10% Security Holder of Issuer |
EXERCISE | 2.50K | $28.44K | Direct |
| Jun 24, 26 | Walinski (Hubert) Director of Issuer |
EXERCISE | 2.50K | $28.44K | Direct |
| Jun 24, 26 | Walinski (Hubert) Director of Issuer |
EXERCISE | 1.15K | $13.17K | Direct |
| Mar 24, 26 | Mull (Craig James) 10% Security Holder of Issuer |
EXERCISE | 83.90K | $1.03M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Cipher Pharmaceuticals, Inc. |
Issuer | 133.25K | Redemption, retraction, cancelation, repurchase |
Deeth, Douglas Norman |
Director of Issuer | 3.84K | Exercise of rights |
Jacobs (Bryan) |
Senior Officer of Issuer | 16.59K | Exercise of options |
Mull (Craig James) |
10% Security Holder of Issuer | 969.95K | Acquisition or disposition in the public market |
Walinski (Hubert) |
Director of Issuer | 3.84K | Exercise of rights |
Fundamentals
Market cap$249.83M
Enterprise value$238.89M
Revenue (TTM)$49.62M
Gross profit$40.40M
EBITDA$26.48M
Net income$28.99M
EPS (TTM)$1.11
Free cash flow$19.21M
Total cash$9.11M
Total debt$367.00K
Book value / share$5.40
Shares outstanding25.42M
Float14.82M
Short % of float—
Dividend yield0.00%
Beta (5Y)0.41
Valuation & profitability ratios
Trailing P/E8.86
Forward P/E19.66
PEG ratio—
Price / sales—
Price / book1.82
EV / revenue4.81
EV / EBITDA9.02
Gross margin81.40%
Operating margin39.23%
Profit margin58.42%
Return on equity23.50%
Return on assets7.97%
Debt / equity0.27
Current ratio1.59
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $50.45M | $33.36M | $21.16M | $20.68M | +51.2% |
| Operating revenue | $50.45M | $33.36M | $21.16M | $20.68M | +51.2% |
| Cost of revenue | $10.03M | $9.26M | $4.07M | $3.99M | +8.3% |
| Gross profit | $40.42M | $24.10M | $17.09M | $16.68M | +67.7% |
| Research & development | $21.00K | $0 | $139.00K | $98.00K | — |
| Selling, general & admin | $16.30M | $12.24M | $5.42M | $4.55M | +33.2% |
| Total operating expense | $23.56M | $16.25M | $6.79M | $5.63M | +44.9% |
| Operating income | $16.86M | $7.85M | $10.30M | $11.05M | +114.9% |
| Net interest income | -$1.17M | $330.00K | $1.87M | $464.00K | -453.0% |
| Pre-tax income | $17.16M | $2.96M | $12.68M | $11.48M | +480.8% |
| Tax provision | -$10.17M | -$8.59M | -$7.70M | -$15.16M | -18.3% |
| Net income | $27.33M | $11.54M | $20.38M | $26.64M | +136.7% |
| Net income to common | $27.33M | $11.54M | $20.38M | $26.64M | +136.7% |
| Basic EPS | 1.07 | 0.47 | 0.82 | 1.05 | +127.7% |
| Diluted EPS | 1.05 | 0.46 | 0.80 | 1.03 | +128.3% |
| EBIT | $16.86M | $7.85M | $10.30M | $11.05M | +114.9% |
| EBITDA | $24.10M | $11.87M | $11.53M | $12.04M | +103.1% |
| Basic shares | 25.48M | 24.56M | 24.86M | 25.38M | +3.7% |
| Diluted shares | 25.99M | 25.10M | 25.48M | 25.80M | +3.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $7.49M | $17.84M | $39.83M | $28.84M | -58.0% |
| Cash & short-term investments | $7.49M | $17.84M | $39.83M | $28.84M | -58.0% |
| Accounts receivable | $11.21M | $13.86M | $5.09M | $6.80M | -19.1% |
| Inventory | $8.19M | $5.79M | $2.98M | $2.15M | +41.4% |
| Total current assets | $28.05M | $38.48M | $48.27M | $38.16M | -27.1% |
| Property, plant & equipment | $569.00K | $680.00K | $402.00K | $481.00K | -16.3% |
| Goodwill & intangibles | $89.46M | $96.20M | $17.47M | $18.46M | -7.0% |
| Total assets | $156.50M | $162.51M | $86.03M | $73.78M | -3.7% |
| Total current liabilities | $25.04M | $19.87M | $5.25M | $9.37M | +26.0% |
| Long-term debt | $5.00M | $40.00M | — | — | -87.5% |
| Total debt | $5.50M | $40.58M | $353.00K | $428.00K | -86.4% |
| Total liabilities | $30.26M | $60.17M | $5.51M | $9.70M | -49.7% |
| Retained earnings | $100.11M | $77.65M | $66.27M | $50.52M | +28.9% |
| Shareholder equity | $126.24M | $102.34M | $80.52M | $64.08M | +23.4% |
| Working capital | $3.00M | $18.61M | $43.02M | $28.79M | -83.9% |
| Net tangible assets | $36.78M | $6.14M | $63.05M | $45.62M | +498.9% |
| Shares issued | 25.28M | 25.60M | 23.99M | 25.06M | -1.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $27.33M | $11.54M | $20.38M | $26.64M | +136.7% |
| Depreciation & amortisation | $7.23M | $4.02M | $1.23M | $989.00K | +80.0% |
| Stock-based compensation | $1.74M | $1.07M | $1.19M | $403.00K | +62.1% |
| Change in working capital | $5.23M | $8.95M | -$3.28M | -$3.03M | -41.6% |
| Operating cash flow | $29.73M | $19.55M | $16.00M | $10.72M | +52.1% |
| Capital expenditure | -$201.00K | -$44.00K | -$21.00K | -$81.00K | -356.8% |
| Investing cash flow | -$71.00K | -$80.04M | -$144.00K | -$81.00K | +99.9% |
| Share buybacks | -$5.38M | -$176.00K | -$5.56M | -$1.99M | -2,957.4% |
| Financing cash flow | -$40.47M | $39.30M | -$5.24M | -$1.91M | -203.0% |
| Free cash flow | $29.52M | $19.50M | $15.98M | $10.64M | +51.4% |
| End cash position | $7.49M | $17.84M | $39.83M | $28.84M | -58.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $12.07M | $12.51M | $12.22M | $12.83M | $13.38M | — | -3.5% |
| Operating revenue | $12.07M | $12.51M | $12.22M | $12.83M | $13.38M | — | -3.5% |
| Cost of revenue | $2.37M | $2.21M | $2.30M | $2.35M | $2.50M | — | +7.2% |
| Gross profit | $9.70M | $10.30M | $9.91M | $10.48M | $10.88M | — | -5.8% |
| Research & development | $0 | $0 | $0 | $0 | $0 | — | — |
| Selling, general & admin | $3.18M | $2.90M | $3.68M | $3.71M | $4.08M | — | +9.8% |
| Total operating expense | $4.96M | $4.70M | $5.49M | $5.51M | $5.89M | — | +5.6% |
| Operating income | $4.73M | $5.59M | $4.43M | $4.97M | $4.99M | — | -15.4% |
| Net interest income | $15.00K | -$51.00K | -$109.00K | -$241.00K | -$345.00K | — | +129.4% |
| Pre-tax income | $3.64M | $4.95M | $4.61M | $4.26M | $6.41M | — | -26.4% |
| Tax provision | -$369.00K | -$1.21M | -$8.70M | -$1.24M | $512.00K | — | +69.6% |
| Net income | $4.01M | $6.16M | $13.31M | $5.50M | $5.89M | — | -34.9% |
| Net income to common | $4.01M | $6.16M | $13.31M | $5.50M | $5.89M | — | -34.9% |
| Basic EPS | 0.16 | 0.24 | — | 0.22 | 0.23 | 0.10 | -33.3% |
| Diluted EPS | 0.15 | 0.24 | — | 0.21 | 0.22 | 0.10 | -37.5% |
| EBIT | $4.73M | $5.00M | $4.43M | $4.97M | $4.99M | — | -5.3% |
| EBITDA | $6.52M | $6.81M | $6.23M | $6.77M | $6.80M | — | -4.2% |
| Basic shares | 25.40M | 25.28M | — | 25.37M | 25.87M | 25.61M | +0.5% |
| Diluted shares | 25.99M | 25.80M | — | 25.95M | 26.51M | 26.20M | +0.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $9.11M | $6.41M | $7.49M | $8.42M | $11.34M | — | +42.1% |
| Cash & short-term investments | $9.11M | $6.41M | $7.49M | $8.42M | $11.34M | — | +42.1% |
| Accounts receivable | $12.14M | $9.75M | $11.21M | $10.13M | $11.87M | — | +24.5% |
| Inventory | $9.24M | $8.20M | $8.19M | $6.71M | $5.58M | — | +12.7% |
| Total current assets | $30.98M | $25.50M | $28.05M | $26.66M | $30.55M | — | +21.5% |
| Property, plant & equipment | $413.00K | $478.00K | $569.00K | $453.00K | $522.00K | — | -13.6% |
| Goodwill & intangibles | $86.83M | $88.29M | $89.46M | $91.09M | $92.73M | — | -1.7% |
| Total assets | $156.89M | $153.28M | $156.50M | $147.50M | $152.39M | — | +2.4% |
| Total current liabilities | $19.51M | $20.37M | $25.04M | $20.43M | $17.76M | — | -4.2% |
| Long-term debt | — | — | $5.00M | $13.00M | $25.00M | $40.00M | — |
| Total debt | $367.00K | $428.00K | $5.50M | $13.39M | $25.45M | — | -14.3% |
| Total liabilities | $19.64M | $20.53M | $30.26M | $33.57M | $42.96M | — | -4.4% |
| Retained earnings | $110.29M | $106.28M | $100.11M | $88.30M | $84.25M | — | +3.8% |
| Shareholder equity | $137.25M | $132.75M | $126.24M | $113.94M | $109.44M | — | +3.4% |
| Working capital | $11.47M | $5.13M | $3.00M | $6.23M | $12.79M | — | +123.5% |
| Net tangible assets | $50.43M | $44.45M | $36.78M | $22.84M | $16.70M | — | +13.4% |
| Shares issued | 25.39M | 25.39M | 25.28M | 25.37M | 25.39M | — | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $4.01M | $6.16M | $13.31M | $5.50M | $5.89M | — | -34.9% |
| Depreciation & amortisation | $1.78M | $1.81M | $1.81M | $1.80M | $1.81M | — | -1.2% |
| Stock-based compensation | $323.00K | $304.00K | $525.00K | $533.00K | $436.00K | — | +6.3% |
| Change in working capital | -$3.60M | -$3.17M | $2.25M | $3.66M | -$914.00K | — | -13.6% |
| Operating cash flow | $3.05M | $4.52M | $8.73M | $10.76M | $6.02M | — | -32.6% |
| Capital expenditure | -$255.00K | -$560.00K | -$118.00K | -$81.00K | — | -$2.00K | +54.5% |
| Investing cash flow | -$255.00K | -$492.00K | -$118.00K | $49.00K | $0 | — | +48.2% |
| Share buybacks | — | — | -$1.66M | -$1.58M | -$2.14M | $0 | — |
| Financing cash flow | $96.00K | -$5.04M | -$9.62M | -$13.60M | -$17.21M | — | +101.9% |
| Free cash flow | $2.79M | $3.96M | $8.61M | $10.68M | $6.02M | — | -29.5% |
| End cash position | $9.11M | $6.41M | $7.49M | $8.42M | $11.34M | — | +42.1% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.19 | 0.15 | -21.0% |
| Mar 2026 | 0.16 | 0.24 | +50.0% |
| Dec 2025 | 0.16 | 0.51 | +229.0% |
| Sep 2025 | 0.13 | 0.21 | +68.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.22 | 2 | $18.20M | +0.3% |
| Next quarter | 0.24 | 2 | $18.55M | +11.4% |
| Current year | 0.81 | 4 | $70.85M | +3.1% |
| Next year | 0.88 | 3 | $81.35M | +14.8% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy1 / 2
Hold1
Sell / Strong sell0 / 0
Held by insiders42.54%
Held by institutions1.28%
Institutions holding4
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
9.74
+0.96% from price
SMA 20
10.07
-2.39% from price
SMA 50
10.57
-7.00% from price
SMA 100
11.21
-12.33% from price
SMA 200
11.54
-14.79% from price
EMA 12
9.85
-0.17% from price
EMA 26
10.09
-2.61% from price
EMA 50
10.48
-6.16% from price
RSI (14)
40.4
Neutral
MACD (12,26,9)
-0.25
Hist -0.00
ATR (14)
0.17
1.71% of price
Realised vol 30D
20.2%
Annualised
Bollinger upper
10.79
20, 2σ
Bollinger lower
9.35
20, 2σ
50 / 200 cross
Death
10.57 vs 11.54
Trend bias
Below 200
-14.79%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.25
Less volatile than market
Correlation to SPY
0.08
Largely independent
Realised vol 30D
20.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-33.3%
Peak to trough
Max drawdown 5Y
-55.4%
Peak to trough
ATR 14
0.17
1.71% of price
Beta (reported)
0.41
5Y monthly, from filing
Short interest
Shares short
11.43K
Prior 48.42K
Change vs prior
-76.4%
Shorts covering
% of float
—
—
% of shares out
0.04%
Against total outstanding
Days to cover
1.0
Liquid
Float
14.82M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 1, 23 | Stifel | UPGRADE | Hold | Speculative Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
Headlines
Cipher Pharmaceuticals Announces the Appointment of Rajiv De Silva to its Board of Directors
CNW Group · 16d ago
Cipher Pharmaceuticals' Ownership Of Certain Abscoria-Related Clinical Data Affirmed by US Court
MT Newswires · 36d ago
Cipher Pharmaceuticals Receives Favourable Decision Confirming Arbitration Award
CNW Group · 36d ago
Cipher Pharmaceuticals Inc (CPHRF) (Q2 2026) Earnings Call Highlights: Epuris Growth and ...
GuruFocus.com · 56d ago
Cipher Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat · 56d ago
Cipher Pharmaceuticals Reports Second Quarter 2026 Results
CNW Group · 57d ago
Cipher Pharmaceuticals Schedules Q2 2026 Earnings Release and Conference Call
CNW Group · 68d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.